Programme

08:30 Registration opens
09:00 Exhibition and Partnering throughout the day
10:00 General Assembly of the Swiss Biotech Association (by invitation only)
Plenary Session
11:00 Welcome Address
Domenico Alexakis, CEO, Swiss Biotech Association
11:10 Key Note I: Transforming Chemistry
Rudolf Hanko, CEO, Siegfried AG
11:30 Key Note II: Innovation@Bayer: Combining Creative Minds With Passion
Monika Lessl, Head of Innovation Strategy, Bayer AG
11:50 Presentation of the Swiss Biotech Report and Panel Discussion
Jürg Zürcher, Ernst & Young AG and Member of the Steering Committee
12:30 Lunch   
13.30 “Investor and Analyst Track” “Compliance”
Presented by KPMG AG
“Emerging Companies”
Presented by Bayer
“Impacts on the value chain”
Presented by S-GE
 
  • Santhera Pharmaceuticals Holding Ltd.
    Thomas Meier, CEO

  • Newron Pharmaceuticals S.p.A.
    Stefan Weber, CEO

  • Addex Therapeutics
    Timothy Dyer, CFO

  • InnoMedica AG
    Jonas Zeller, Head of Finance

  • Molecular Partners
    Andreas Emmenegger, CFO

  • Probiodrug
    Konrad Glund, CEO

  • Nordic Nanovector
    Luigi Costa, CEO

 

The right balance between 
too much and too little – compliance – get inspired
Martin Rohrbach, Partner & Head of Audit Basel, KPMG AG      

Impact of emerging regulations, codes and
guidelines on how biotech
companies conduct business
Kathleen Tench, Director Forensic, KPMG AG   

When does compliance become
a management principle? 
Peter Herrmann, CCO
Actelion Pharmaceuticals Ltd.
 

Compliance program for early research functions
Jan Wesiack, Regional Compliance Manager Europe, NIBR Basel, Novartis Pharma AG

Research with Human Biological Material and Data 
Adrian Zumbach, Senior Legal Counsel at Novartis Institutes of BioMedical Research (NIBR), Novartis Pharma AG

Structuring the insurance portfolio of Life Science Companies
Jörg Schmidt, Schmidt
Versicherungs Treuhand AG

Ethics as a business case for
the right balance in compliance
Martijn de Kiewit, Director Forensic, KPMG AG

  • Genkyotex SA
    Elias Papatheodorou, CEO

  • Quartz Bio SA
    Jérôme Wojcik, CEO

  • Gour Medical SA
    Serge Goldner, CEO

  • Tolerys SA
    Pierre-Marie
    Guyonvarc'h, CEO


  • Inthera Bioscience
    Ulrich Kessler, CEO

  • Chrondonest
    Thierry Schwitzguébel

  • Memo-Therapeutics
    Armin W. Mäder, CEO

  • MaxiVax
    Nicolas Mach, CSO 

Introduction on Value Chains in Biotech
Hans Mies, Director Intl. Corporate Tax at KPMG AG, value chain management expert

New Markets: International Cooperations
Jakob Dynnes Hansen, CFO, Evolva

New Markets – benefits of international R&D cooperation
Andreas Gut, Swiss EUREKA Project Coordinator, State Secretariat for Education, Research and Innovation SERI

Innovation: Technology Fusion:
Biotech meets IT
Arthur Queval, Founder & CEO, Qloudlab

Processes and Structures: 
Lean and mean:
Biotech structures in Switzerland

Panel Discussion

Moderation:
Monika Jones

17.00 Apéro and Wrap-Up of the Day - hosted by Bayer AG 
19.00 End

Programme Track “Compliance”

Presented by KPMG

Speakers to be defined.

13.30 - 13.45Intro – The value of compliance?Martin Rohrbach
   
13.45 - 15.00Session 1
Impact of emerging regulations, codes and guidelines on how biotech companies conduct business
Regulatory: Sunshine Act, Human Research Law & Nagoya Protocol
Key Findings from KPMG’s Global Anti-Bribery and Corruption Survey
Clinical research compliance a competitive advantage?
Kathy Tench
   
15.30 - 17.00Session 2
 Ethics as a business case: having the right strategy
Martijn de Kiewit



Programme Track “Impacts on the value chain”

Presented by S-GE

  • Introduction on Value Chains in Biotech
  • New Markets International Cooperations
  • Innovation Technology Fusion: Biotech meets IT
  • Processes and Structures Lean and mean: Biotech structures in Switzerland
  • Panel Discussion

Moderation: Monika Jones